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using a Kruskal-Wallis test with a Dunn’s multiple comparison test; a
Mann Whitney t test was used for cartilage. P < 0.05 was considered
signiﬁcant. All procedures were approved by institutional animal care
and use committees.
Results: Osteochondral fragments were successfully created and multiple
clinical and morphologic changes consistent with early OA were
demonstrated. OC injured horses exhibited a decrease in forelimb
symmetry (P < 0.001) at week 2 on the force plate, indicating pain. No
further differences were seen over time or between groups. By week 16,
range of motion decreased in 9/11 (82%) OC injured limbs compared to
no change in sham and control limbs. Subjective joint effusion scores
increased in OC injured limbs compared to baseline throughout the
entire study period (P < 0.001). Radiographic scores showed subtle but
signiﬁcant change in the OC injured limbs (Table 1). Arthroscopically,
synovial membrane from OC injured joints exhibited mild changes
(hyperemia, villus thickening, and proliferation). However, cartilage
damage within the joint was more pronounced (Table 1). Histologically,
chondrocyte necrosis and proliferation (repair) were signiﬁcantly greater
in OC injured cartilage compared to sham cartilage, with the majority of
changes restricted to the superﬁcial zone (Table 1). A non-inﬂammatory
ﬁbrotic reaction was seen in OC injured synovium.
Conclusions: Creation of an OC fragment in the equine MCP joint results
in acute traumatic joint injury that has mild but consistent clinical and
morphological features of early OA. This non-terminal injury model will
be useful for deﬁning biomarker changes of early OA and for monitoring
response to therapy of this disease.
140
EX-VIVO EFFECTS OF MELOXICAM ON CHONDROCYTE METABOLISM
IN OSTEOARTHRITIC CANINE CARTILAGE
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Purpose: This study assessed the effect of meloxicam on chondrocyte
metabolism in a naturally occurring osteoarthritic (OA) canine cartilage
model.
Methods: Cartilage harvest from 21 dogs with coxofemoral OA at time of
total hip replacement (THR). Sixteen dogs did not receive NSAIDs prior
to THR and cartilage harvest (Group 1). Five dogs received meloxicam
for at least 14 days prior to THR and cartilage harvest (Group 2).
Cartilage Explant Culturing: Group 1 – Cartilage with control
0.0ug/ml(Cm:control) and meloxicam media dilutions (0.3, 3.0, 30.0
ug/ml): Explants and media were collected on days 3, 12, and 30.
Group 2 – Cultured with culture medium alone (MPM:Cm).
Tissue Matrix Analysis: (1) surgical sample and (1) explant from each
animal in each test group were collected on days 3, 12, and 30 of
culture and analyzed for total sulfated GAG, total collagen content via
hydroxyproline (HP) measurement and cartilage DNA content.
Media Analysis: Chondroitin sulfate 846 (CS-846), Nitric oxide (NO),
Prostaglandin E2 (PGE2), Matrix metalloproteinases (MMP-2, -3, -13),
Aggrecan and Collagen II, Proteinases (MMP-1, -2, -3, -9, -13,
aggrecanase-1, aggrecanase-2), Proteinase inhibitors (TIMP-1, -2, -3),
Inﬂammatory indicators (IL-1b, TNF-a, COX-1, COX-2 and INOS), House
keeping gene (GAPDH)
Statistical Analysis: For comparisons between group 1 subgroups
(Cm:control) and (Mm0.3, Mm3.0, and Mm30.0) where subgroups
included the same dogs, a repeated measures model was utilized.
For comparisons between MPM:Cm, and Cm:control where each group
included different dogs, an analysis of variance (ANOVA) test was used.
Multiple comparisons were adjusted using Tukey’s test. Signiﬁcance level
was set at a = 0.05.
Results:
In vitro:
– Cartilage matrix analysis: Meloxicam had no effect on GAG, HP
or DNA content compared between Cm:control, Mm 0.3, 3.0, 30.0
subgroups at any time point.
– Media analysis: Signiﬁcant changes: GAG decreased in all group1
subgroups on days 12 and 30 compared to day 3. CS-846 decreased
between day 3 and days 12 and 30 in the Cm:control subgroup.
PGE2 was lower on day 3 in all three meloxicam treated subgroups
compared to Cm:control. Aggrecan was greater days 12 and 30
compared to day 0 for the Cm:control group. MMP-3 was decreased
in Mm0.3, 3.0, 30.0 subgroups between days 3 and 30. Aggrecanase-2
was decreased in all group 1 subgroups on all days compared
to baseline. INOS decreased in all group 1 subgroups on all days
compared to day 0.
Ex vivo:
– Cartilage matrix analysis: Meloxicam pretreatment had no effect on
GAG, HP or DNA content compared between Cm:control, at any time
point.
– Media analysis: Meloxicam pretreated cartilage showed no
differences within or between MPM:cm and Cm:control groups in
GAG, HP or DNA content at any time point. NO – increase in MPM:cm
media on day 3 compared to Cm:control. PGE2 – decrease from day 3
to day 30 in both groups. Proteinases – Media MMP-3 concentrations
were less days 12 and 30 compared to day 3 in the MPM:cm group.
Media MMP-13 was greater in MPM:cm compared to Cm:control on
days 3 and 12. Gene Expression – Cm:control MMP2 was increased
days 3, 12, and 30 compared to day 0. MPM:cm group MMP-2 was
lower than Cm:control on days 3 and 12. Inﬂammatory Indicators –
COX-2 gene expression was greater day 3 compared to day 30 in the
MPM:cm group.
Conclusions: These data suggest that meloxicam treatment of naturally
occurring OA cartilage did not induce degradation over 30 days of
treatment and in some measures (media CS-846 and MMP-3) appeared
to prevent degradation at concentrations up to 100 times the expected
synovial concentrations. Meloxicam effectively decreased inﬂammatory
mediator production (PGE2) in OA chondrocytes. Ex-vivo pretreatment
of OA cartilage with meloxicam did not appear to induce degradative
processes in the cartilage as the cartilage was evaluated for 30 days
following removal of drug.
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IN A CANINE IN VIVO MODEL, ARTIFICIALLY ENHANCED
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Background: Osteoarthritis is a highly prevalent disease, age being the
main risk factor. The age related accumulation of advanced glycation
endproducts (AGEs) adversely affects the mechanical and biochemical
properties of cartilage.
Purpose: The hypothesis that accumulation of cartilage AGEs predispose
to the development of osteoarthritis was tested in vivo in a canine
model.
Methods: To artiﬁcially increase cartilage AGEs, right knee joints of 8
dogs were repeatedly injected with ribose/threose in PBS, left joints with
PBS alone as a control. Subsequently minimal surgically applied cartilage
damage was induced and loading restrained as much as possible.
Thirty weeks after surgery joint tissues of all dogs were analyzed for
biochemical (PG turnover), macroscopic, and histological features of OA.
The Utrecht University Medical Ethical Committee for animal studies
approved the study.
